IRIS
LIAKOULI, Vasiliki
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.308
EU - Europa 1.252
AS - Asia 307
SA - Sud America 1
Totale 3.868
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.299
IE - Irlanda 607
GB - Regno Unito 232
CN - Cina 164
SG - Singapore 122
DE - Germania 121
GR - Grecia 112
IT - Italia 81
SE - Svezia 42
UA - Ucraina 27
TR - Turchia 13
CA - Canada 8
FI - Finlandia 7
FR - Francia 7
RU - Federazione Russa 5
BE - Belgio 4
HK - Hong Kong 3
IN - India 3
KR - Corea 2
AT - Austria 1
BR - Brasile 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
MK - Macedonia 1
PT - Portogallo 1
RO - Romania 1
Totale 3.868
Salva come PNG Salva come JPEG
Città #
Dublin 607
Chicago 533
Wilmington 441
Falls Church 338
Jacksonville 177
Santa Clara 120
Princeton 110
Roxbury 108
Chandler 103
Bremen 102
Medford 75
Singapore 63
Beijing 56
Des Moines 41
Cambridge 35
Naples 17
Nanjing 13
Ann Arbor 12
Hefei 11
Caserta 9
Jinan 9
Hebei 8
New York 8
Ottawa 8
Boardman 7
Ningbo 7
Shenyang 7
Tianjin 7
Ashburn 6
Kunming 6
Bagnoli Irpino 5
Dearborn 5
Hangzhou 5
Marsico Nuovo 5
Woodbridge 5
Athens 4
Brussels 4
Kostroma 4
Mugnano di Napoli 4
Rome 4
San Mateo 4
Taizhou 4
Changsha 3
Jiaxing 3
Napoli 3
Redwood City 3
Seattle 3
Taiyuan 3
Auburn Hills 2
Catanzaro 2
Guangzhou 2
Haikou 2
Helsinki 2
Hong Kong 2
London 2
Redmond 2
Shanghai 2
Amadora 1
Avellino 1
Aversa 1
Belo Horizonte 1
Brno 1
Central District 1
Chengdu 1
Crespellano 1
Fuzhou 1
Galati 1
Grumo Appula 1
Guizhou 1
Gunzenhausen 1
Huzhou 1
Lanzhou 1
Lappeenranta 1
Los Angeles 1
Manchester 1
Munich 1
Nanchang 1
Norwalk 1
Oakland 1
Quzhou 1
Rockville 1
Sammamish 1
San José 1
San Severo 1
Shaoxing 1
Skopje 1
Stockholm 1
Torre Dei Passeri 1
Wuhan 1
Xiamen 1
Xiangfen 1
Yicheng 1
Zhengzhou 1
Totale 3.169
Salva come PNG Salva come JPEG
Nome #
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 1.307
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 91
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population 61
Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 55
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 42
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 39
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 38
Association of FASG670A gene polymorphism with systemic sclerosis. 38
Modificazioni della nitrossido-sintasi neuronale (nNOS) nella cute dei pazienti con sclerosi sistemica (SSc). 37
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 35
AB0226 Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC). 35
Angiogenic cytokines and growth factors in systemic sclerosis 34
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 34
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 33
Cardiovascular disease in primary sjögren’s syndrome 33
VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION 33
AB0244 Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC) 33
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome 33
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 32
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 31
H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 31
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial 31
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 30
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome 29
Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC) 28
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 27
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS 27
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus 27
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 26
IMPAIREMENT OF ENDOTHELIAL DIFFERENTIATION FROM MESENCHYMAL STEM CELLS (MSC) IN SYSTEMIC SCLEROSIS (SSC): A NEW TOOL IN PATHOGENETIC MECHANISM 26
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 25
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 25
Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare 25
Subclinical and clinical atherosclerosis in rheumatoid arthritis: Results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 25
AB0248 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 24
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 24
. FRI0437 Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from SSC Patients Induces an Anti Angiogenetic Effect, when Co-Cultured with Endothelial Cells. 24
Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? 24
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 23
Interleukin-33 and its receptor st2 may serve as 'alarmin' system of the progressing damage to the skin and visceral organs of systemic sclerosis (ssc) patients 23
Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives 23
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis 23
Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T cells in RA patients and correlation with atherosclerotic damage 23
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease. 23
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy 23
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 23
Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC) 22
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 22
Potential of stem cells in the treatment of rheumatic didease 22
Cellular players in angiogenesis during the course of systemic sclerosis 21
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 21
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 21
Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis: pathogenetic implication. 21
Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implication. 21
Pigment epithelium derived factor secreted by ssc fibroblasts inhibits angio and vasculogenesis in vitro. 21
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 21
Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis 20
Interstitial lung disease in systemic sclerosis: current and future treatment 20
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease 20
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 20
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 20
SAT0191 Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren's syndrome. 20
The Vessels Contribute to Fibrosis in Systemic Sclerosis 20
Use of Rituximab in the Management of Sjögren’s Syndrome 20
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosis. 20
Endothelial Progenitor Cells (EPC) characterization in systemic sclerosis (SSc) patients. 20
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 20
Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor 20
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 19
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions 19
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature 19
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study 19
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 19
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies 19
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients 19
SDF-1 expression in the skin of SSc patients. 19
Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications 19
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 19
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 19
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 19
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 19
Methotrexate: an old new drug in autoimmune disease 19
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine 19
Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma 19
Macitentan inhibits the transforming growth factor-βprofibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. 19
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 18
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 18
Pathogenesis of the Endothelial Damage and Related Factors 18
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy 18
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI) 18
Tocilizumab for the treatment of adult-onset Still's disease: results from a case series 18
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset 17
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 17
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study 17
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients 17
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 17
Decreased expression of angiopoietin 1 on perivascular mesenchymalstemcells from SSc patients induces an anti angiogenic effect, when co-cultured with endothelial cells 17
Pigment Epithelium Derived Factor Secreted By Activated Fibroblasts Can Contribute To Impaired Angio and Vasculogenesis In Scleroderma. 17
 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 17
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 17
Totale 3.773
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020236 0 0 0 0 10 3 120 44 34 11 10 4
2020/2021360 7 1 16 20 68 2 105 10 12 8 109 2
2021/20221.446 73 133 258 115 322 30 24 25 43 30 84 309
2022/20231.336 206 85 308 14 138 37 0 27 503 2 5 11
2023/2024356 18 9 3 7 160 10 6 12 4 7 9 111
2024/2025162 1 0 3 31 127 0 0 0 0 0 0 0
Totale 4.012